World's First Allogeneic Artificial Regenerated Platelet Clinical Study Succeeds in Shanghai

Background

Platelet shortages represent a persistent challenge in healthcare, particularly for patients experiencing thrombocytopenia, or critically low platelet counts. This condition is common among those with acute leukemia undergoing chemotherapy, individuals with aplastic anemia, and children recovering from surgery for complex congenital heart disease. Traditional platelet transfusions rely on volunteer blood donations. These face significant limitations, including a short storage life, the need for compatibility matching, and risks of contamination or immune reactions. Such constraints can lead to treatment delays and increased patient risk when adequate supplies are unavailable.

Research into stem cell-based alternatives has sought to develop more reliable sources of platelets to address these clinical gaps.

What was achieved

On September 5, 2025, Shanghai Children's Medical Center announced the successful completion of the world's first clinical infusion study of allogeneic artificial regenerated platelets, known as iPLT or human induced pluripotent stem cell-derived platelets. The research was led by Professor Shen Shuhong of the Department of Hematology in collaboration with teams from oncologic surgery and cardiothoracic surgery.

Three patients received the iPLT infusions, encompassing cases of acute leukemia, aplastic anemia, and post-operative complex congenital heart disease including Tetralogy of Fallot. The first infusion occurred on March 9, 2025. No study drug-related serious adverse events (SAE) or dose-limiting toxicities (DLT) were reported. The preliminary results confirmed the safety and good tolerability of iPLT in these patients.

Sun Xinyan, director of the hospital's Clinical Research Management Center, noted that the successful initial translation and safety validation of this artificial regenerated platelet technology provides a new direction for addressing platelet supply shortages and associated safety issues. She described it as an early exploratory stage, with data from the three patients establishing a foundation for further research.

How it works

Platelets are small cell fragments in blood that are essential for clotting and preventing excessive bleeding. In patients with thrombocytopenia, transfusions are used to reduce the risk of hemorrhage. Conventional platelets are collected from human donors but must be used quickly, require careful matching, and carry risks of reactions or shortages.

The iPLT approach uses cells from a single healthy donor that are reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs have the ability to self-renew and differentiate into various cell types. In a controlled laboratory setting, they are scaled up and directed to form megakaryocytes, the precursor cells that release platelets. This process enables production of a standardized allogeneic product that can be prepared for use across multiple recipients and stored for longer periods than traditional donor platelets, reducing reliance on frequent individual donations.

What it means for international patients

Shanghai Children's Medical Center operates an International Medical Services department that serves patients and families from overseas. It provides English language support along with a network of multilingual volunteers and has experience treating international children with complex pediatric conditions, including those in hematology, oncology, and cardiology.

As this represents preliminary clinical research rather than an established treatment, broader availability or specific protocols for international patients have not been detailed in reports. Patients interested in regenerative medicine approaches for blood disorders, congenital heart conditions, or potential participation in related studies must confirm eligibility, current trial status, and any applicable criteria directly with the hospital. Contact can be made through the international department.

About the hospital

Shanghai Children's Medical Center is located in the Pudong New Area of Shanghai. It is a public tertiary (Grade III Class A) pediatric specialty hospital affiliated with Shanghai Jiao Tong University School of Medicine and designated as a National Children's Medical Center. Founded in 1998 through a partnership between the Shanghai municipal government and Project HOPE, it was the first children's specialty hospital in China to achieve JCI international accreditation.

The hospital is recognized as one of the top facilities in China for pediatric congenital heart disease and hematology/oncology. It integrates clinical care, teaching, research, and prevention. An International Medical Services department supports overseas patients.